Several immune escape patterns in non-Hodgkin's lymphomas

被引:89
|
作者
Laurent, Camille [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Charmpi, Konstantina [7 ,8 ]
Gravelle, Pauline [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Tosolini, Marie [2 ,3 ,4 ,5 ,6 ,7 ]
Franchet, Camille [1 ]
Ysebaert, Loic [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Brousset, Pierre [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Bidaut, Alexandre [9 ]
Ycart, Bernard [7 ,8 ]
Fournie, Jean-Jacques [2 ,3 ,4 ,5 ,6 ,7 ]
机构
[1] Inst Univ Canc Oncopole Toulouse, Toulouse, France
[2] Ctr Rech Cancerol Toulouse, INSERM UMR1037, Toulouse, France
[3] Univ Toulouse 3, F-31062 Toulouse, France
[4] ERL 5294 CNRS, Toulouse, France
[5] Programme Hosp Univ Cancerol CAPTOR, Toulouse, France
[6] Inst Carnot Lymphome CALYM, Toulouse, France
[7] Lab Excellence TOUCAN, Toulouse, France
[8] CNRS UMR5224, Lab Jean Kuntzmann, Grenoble, France
[9] Inst Rech Pierre Fabre, Castres, France
来源
ONCOIMMUNOLOGY | 2015年 / 4卷 / 08期
关键词
immune escape; lymphoma; PD-1/PD-L1; axis; TMA; transcriptomes; B-CELL LYMPHOMA; DEATH LIGAND 1; FOLLICULAR LYMPHOMA; T-CELLS; KAPPA-B; EXPRESSION; BLOCKADE; PD-1; SURVIVAL; CANCER;
D O I
10.1080/2162402X.2015.1026530
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Follicular Lymphomas (FL) and diffuse large B cell lymphomas (DLBCL) must evolve some immune escape strategy to develop from lymphoid organs, but their immune evasion pathways remain poorly characterized. We investigated this issue by transcriptome data mining and immunohistochemistry (IHC) of FL and DLBCL lymphoma biopsies. A set of genes involved in cancer immune-evasion pathways (Immune Escape Gene Set, IEGS) was defined and the distribution of the expression levels of these genes was compared in FL, DLBCL and normal B cell transcriptomes downloaded from the GEO database. The whole IEGS was significantly upregulated in all the lymphoma samples but not in B cells or other control tissues, as shown by the overexpression of the PD-1, PD-L1, PD-L2 and LAG3 genes. Tissue microarray immunostainings for PD-1, PD-L1, PD-L2 and LAG3 proteins on additional biopsies from 27 FL and 27 DLBCL patients confirmed the expression of these proteins. The immune infiltrates were more abundant in FL than DLBCL samples, and the microenvironment of FL comprised higher rates of PD-1(+) lymphocytes. Further, DLBCL tumor cells comprised a higher proportion of PD-1+, PD-L1(+), PD-L2(+) and LAG3(+) lymphoma cells than the FL tumor cells, confirming that DLBCL mount immune escape strategies distinct from FL. In addition, some cases of DLBCL had tumor cells co-expressing both PD-1, PD-L1 and PD-L2. Among the DLBCLs, the activated B cell (ABC) subtype comprised more PD-L1(+) and PD-L2(+) lymphoma cells than the GC subtype. Thus, we infer that FL and DLBCL evolved several pathways of immune escape.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Large-scale microarray profiling reveals four stages of immune escape in non-Hodgkin lymphomas
    Tosolini, Marie
    Algans, Christelle
    Pont, Frederic
    Ycart, Bernard
    Fournie, Jean-Jacques
    ONCOIMMUNOLOGY, 2016, 5 (07):
  • [2] Non-Hodgkin's Lymphomas
    Zelenetz, Andrew D.
    Abramson, Jeremy S.
    Advani, Ranjana H.
    Andreadis, C. Babis
    Byrd, John C.
    Czuczman, Myron S.
    Fayad, Luis
    Forero, Andres
    Glenn, Martha J.
    Gockerman, Jon P.
    Gordon, Leo I.
    Harris, Nancy Lee
    Hoppe, Richard T.
    Horwitz, Steven M.
    Kaminski, Mark S.
    Kim, Youn H.
    LaCasce, Ann S.
    Mughal, Tariq I.
    Nademanee, Auyporn
    Porcu, Pierluigi
    Press, Oliver
    Prosnitz, Leonard
    Reddy, Nashitha
    Smith, Mitchell R.
    Sokol, Lubomir
    Swinnen, Lode
    Vose, Julie M.
    Wierda, William G.
    Yahalom, Joachim
    Yunus, Furhan
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2010, 8 (03): : 288 - 334
  • [3] Non-Hodgkin's Lymphomas
    Zelenetz, Andrew D.
    Abramson, Jeremy S.
    Advani, Ranjana H.
    Andreadis, C. Babis
    Bartlett, Nancy
    Bellam, Naresh
    Byrd, John C.
    Czuczman, Myron S.
    Fayad, Luis E.
    Glenn, Martha J.
    Gockerman, Jon P.
    Gordon, Leo I.
    Harris, Nancy Lee
    Hoppe, Richard T.
    Horwitz, Steven M.
    Kelsey, Christopher R.
    Kim, Youn H.
    LaCasce, Ann S.
    Nademanee, Auayporn
    Porcu, Pierluigi
    Press, Oliver
    Pro, Barbara
    Reddy, Nashitha
    Sokol, Lubomir
    Swinnen, Lode J.
    Tsien, Christina
    Vose, Julie M.
    Wierda, William G.
    Yahalom, Joachim
    Zafar, Nadeem
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2011, 9 (05): : 484 - 560
  • [4] Epratuzumab in non-Hodgkin's lymphomas
    Furman R.R.
    Coleman M.
    Leonard J.P.
    Current Treatment Options in Oncology, 2004, 5 (4) : 283 - 288
  • [5] Radiotherapy for Non-Hodgkin Lymphomas
    Imber, Brandon S.
    Yahalom, Joachim
    CANCER JOURNAL, 2020, 26 (03) : 217 - 230
  • [6] Immune Response to Combination Therapy for Non-Hodgkin Lymphomas
    Weiss, Robert F.
    Miller, Merlin G.
    Cronin, John F.
    PLOS ONE, 2013, 8 (12):
  • [7] Ofatumumab in the treatment of non-Hodgkin's lymphomas
    Karlin, Lionel
    Coiffier, Bertrand
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (07) : 1085 - 1091
  • [8] Fibrosis in Hodgkin and non-Hodgkin lymphomas
    Tataroglu, Canten
    Sarioglu, Suelen
    Kargi, Aydanur
    Ozkal, Sermin
    Aydin, Oezlem
    PATHOLOGY RESEARCH AND PRACTICE, 2007, 203 (10) : 725 - 730
  • [9] Obinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomas
    Gabellier, Ludovic
    Cartron, Guillaume
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2016, 7 (02) : 85 - 93
  • [10] Management of unfit patients with unfavourable non-Hodgkin's lymphomas
    Soubeyran, Pierre
    Mertens, Cecile
    Bellera, Carine
    Mathoulin-Pelissier, Simone
    Rainfray, Muriel
    CANCER TREATMENT REVIEWS, 2009, 35 (06) : 528 - 532